Literature DB >> 9106751

Orphan neuropeptide NocII, a putative pronociceptin maturation product, stimulates locomotion in mice.

S Florin1, C Suaudeau, J C Meunier, J Costentin.   

Abstract

NocII is a heptadecapeptide whose sequence lies immediately downstream of nociceptin, the newly discovered natural agonist of the ORL1 receptor, in pronociceptin, nociceptin's precursor polypeptide. Since the sequence of NocII is framed by putative convertase excision sites and it totally conserved across murine and human species, we have sought to determine whether this orphan neuropeptide might by physiologically significant, i.e. endowed with central biological activity in vivo. Intracerebroventricular administration of 10 and 100 ng of NocII increased locomotion in mice. However, unlike nociceptin, which stimulates both the horizontal and vertical (rearing) components of locomotion, NocII affected only the horizontal component. The motor stimulant action of NocII appears to depend largely on dopamine transmission since it is totally reversed by the D1 or the D2 dopamine receptor antagonists SCH 23390 and haloperidol. NocII does not modify the number of explored holes in the hole board test, indicating that, unlike nociceptin, the orphan peptide does not affect exploratory behavior in mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106751     DOI: 10.1097/00001756-199702100-00025

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  9 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 2.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Nociceptin, Phe(1)psi-nociceptin(1 - 13), nocistatin and prepronociceptin(154 - 181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro.

Authors:  M Connor; C W Vaughan; E A Jennings; R G Allen; M J Christie
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain.

Authors:  V Laudenbach; G Calo; R Guerrini; G Lamboley; J F Benoist; P Evrard; P Gressens
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Genome-wide census and expression profiling of chicken neuropeptide and prohormone convertase genes.

Authors:  K R Delfino; B R Southey; J V Sweedler; S L Rodriguez-Zas
Journal:  Neuropeptides       Date:  2009-12-14       Impact factor: 3.286

6.  Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Authors:  Ludovico Arcuri; Riccardo Viaro; Simone Bido; Francesco Longo; Mariangela Calcagno; Pierre-Olivier Fernagut; Nurulain T Zaveri; Girolamo Calò; Erwan Bezard; Michele Morari
Journal:  Neurobiol Dis       Date:  2016-01-22       Impact factor: 5.996

7.  Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test.

Authors:  Elaine C Gavioli; Giles A Rae; Girolamo Calo'; Remo Guerrini; Thereza C M De Lima
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

8.  Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice.

Authors:  Jinhua Wu; Hong Zou; Judith A Strong; Jun Yu; Xuedong Zhou; Qinglian Xie; Guoping Zhao; Meilei Jin; Lei Yu
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

9.  The Effect of Pedal Peptide-Type Neuropeptide on Locomotor Behavior and Muscle Physiology in the Sea Cucumber Apostichopus japonicus.

Authors:  Kui Ding; Libin Zhang; Xinhao Fan; Xueying Guo; Xiang Liu; Hongsheng Yang
Journal:  Front Physiol       Date:  2020-10-22       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.